Glycoproteomics-based signatures of cancer cell lines
Pirro, M.

Citation
Pirro, M. (2021, September 21). *Glycoproteomics-based signatures of cancer cell lines*. Retrieved from https://hdl.handle.net/1887/3212951

References

1.   Stowell, S.R., T. Ju, and R.D. Cummings, *Protein glycosylation in cancer.* Annu Rev Pathol, 2015. **10**: p. 473-510.

2.   Colley, K.J., A. Varki, and T. Kinoshita, *Cellular Organization of Glycosylation*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 41-49.

3.   Varki, A., *Biological roles of glycans.* Glycobiology, 2017. **27**(1): p. 3-49.

4.   Moremen, K.W., M. Tiemeyer, and A.V. Nairn, *Vertebrate protein glycosylation: diversity, synthesis and function.* Nat Rev Mol Cell Biol, 2012. **13**(7): p. 448-62.

5.   Pinho, S.S. and C.A. Reis, *Glycosylation in cancer: mechanisms and clinical implications.* Nat Rev Cancer, 2015. **15**(9): p. 540-55.

6.   Stanley, P., N. Taniguchi, and M. Aebi, *N-Glycans*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 99-111.

7.   Spiro, R.G., *Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds.* Glycobiology, 2002. **12**(4): p. 43R-56R.

8.   Stanley, P. and R.D. Cummings, *Structures Common to Different Glycans*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 161-178.

9.   Brockhausen, I. and P. Stanley, *O-GalNAc Glycans*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 113-123.

10.   Ferreira, J.A., et al., *Protein glycosylation in gastric and colorectal cancers: Toward cancer detection and targeted therapeutics.* Cancer Lett, 2017. **387**: p. 32-45.

11.   Beckwith, D.M. and M. Cudic, *Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.* Semin Immunol, 2020: p. 101389.

12.   Holst, S., M. Wuhrer, and Y. Rombouts, *Glycosylation characteristics of colorectal cancer.* Adv Cancer Res, 2015. **126**: p. 203-56.

13.   Hirano, K., et al., *Expression of LacdiNAc groups on N-glycans among human tumors is complex.* Biomed Res Int, 2014. **2014**: p. 981627.

14.   Jin, C., et al., *Structural Diversity of Human Gastric Mucin Glycans.* Mol Cell Proteomics, 2017. **16**(5): p. 743-758.

15.   Blanas, A., et al., *Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy.* Front Oncol, 2018. **8**: p. 39.

16.   Munkley, J. and D.J. Elliott, *Hallmarks of glycosylation in cancer.* Oncotarget, 2016. **7**(23): p. 35478-89.

17.   Sawanobori, A., et al., *A glycoproteomic approach to identify novel glycomarkers for cancer stem cells.* Proteomics, 2016. **16**(24): p. 3073-3080.

18.   Banazadeh, A., et al., *Recent advances in mass spectrometric analysis of glycoproteins.* Electrophoresis, 2017. **38**(1): p. 162-189.

19.   Niessen, J.K.a.W., *Analyzing Biomolecular Interactions by Mass Spectrometry*. 2015: Wiley-VCH.

20.   Wuhrer, M., et al., *Glycoproteomics based on tandem mass spectrometry of glycopeptides.* J Chromatogr B Analyt Technol Biomed Life Sci, 2007. **849**(1-2): p. 115-28.

21.   Jensen, P.H., et al., *Structural analysis of N- and O-glycans released from glycoproteins.* Nat Protoc, 2012. **7**(7): p. 1299-310.

22.   Rudd, P., et al., *Glycomics and Glycoproteomics*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 653-666.

23.   Hanisch, F.G., et al., *Chemical de-O-glycosylation of glycoproteins for application in LC-based proteomics.* Proteomics, 2009. **9**(3): p. 710-9.

24.   Pan, S., et al., *Mass spectrometry based glycoproteomics--from a proteomics perspective.* Mol Cell Proteomics, 2011. **10**(1): p. R110 003251.

A

25.   McAlister, G.C., et al., *MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes.* Anal Chem, 2014. **86**(14): p. 7150-8.

26.   Wang, Z., et al., *High-throughput and Deep-proteome Profiling by 16-plex Tandem Mass Tag Labeling Coupled with Two-dimensional Chromatography and Mass Spectrometry.* J Vis Exp, 2020(162).

27.   Wang, Z., et al., *27-Plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease.* Anal Chem, 2020. **92**(10): p. 7162-7170.

28.   O'Connor, B.F., D. Monaghan, and J. Cawley, *Lectin Affinity Chromatography (LAC).* Methods Mol Biol, 2017. **1485**: p. 411-420.

29.   Taylor, M.E., et al., *Discovery and Classification of Glycan-Binding Proteins*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 361-372.

30.   Brown, G.D., J.A. Willment, and L. Whitehead, *C-type lectins in immunity and homeostasis.* Nat Rev Immunol, 2018. **18**(6): p. 374-389.

31.   van Kooyk, Y., J.M. Ilarregui, and S.J. van Vliet, *Novel insights into the immunomodulatory role of the dendritic cell and macrophage-expressed C-type lectin MGL.* Immunobiology, 2015. **220**(2): p. 185-92.

32.   Liu, F.T. and G.A. Rabinovich, *Galectins as modulators of tumour progression.* Nat Rev Cancer, 2005. **5**(1): p. 29-41.

33.   Jegouzo, S.A., et al., *Organization of the extracellular portion of the macrophage galactose receptor: a trimeric cluster of simple binding sites for N-acetylgalactosamine.* Glycobiology, 2013. **23**(7): p. 853-64.

34.   van Vliet, S.J., E. Saeland, and Y. van Kooyk, *Sweet preferences of MGL: carbohydrate specificity and function.* Trends Immunol, 2008. **29**(2): p. 83-90.

35.   Diniz, A., et al., *The Plasticity of the Carbohydrate Recognition Domain Dictates the Exquisite Mechanism of Binding of Human Macrophage Galactose-Type Lectin.* Chemistry, 2019. **25**(61): p. 13945-13955.

36.   Marcelo, F., et al., *Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands.* J Biol Chem, 2019. **294**(4): p. 1300-1311.

37.   Takada, A., et al., *Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.* J Virol, 2004. **78**(6): p. 2943-7.

38.   van Vliet, S.J., et al., *Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells.* Int Immunol, 2005. **17**(5): p. 661-9.

39.   van Vliet, S.J., et al., *Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45.* Nat Immunol, 2006. **7**(11): p. 1200-8.

40.   Ju, T., et al., *Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers.* Proteomics Clin Appl, 2013. **7**(9-10): p. 618-31.

41.   Zizzari, I.G., et al., *MGL Receptor and Immunity: When the Ligand Can Make the Difference.* J Immunol Res, 2015. **2015**: p. 450695.

42.   Beatson, R., et al., *The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL.* PLoS One, 2015. **10**(5): p. e0125994.

43.   Kurze, A.K., et al., *Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells.* Cell Commun Signal, 2019. **17**(1): p. 107.

44.   Sahasrabudhe, N.M., et al., *MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma.* Front Oncol, 2019. **9**: p. 29.

45.	Lenos, K., et al., *MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.* Oncotarget, 2015. **6**(28): p. 26278-90.

46.	Saeland, E., et al., *The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma.* Cancer Immunol Immunother, 2007. **56**(8): p. 1225-36.

47.	Rawla, P., T. Sunkara, and A. Barsouk, *Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.* Prz Gastroenterol, 2019. **14**(2): p. 89-103.

48.	Labianca, R., et al., *Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.* Ann Oncol, 2013. **24 Suppl 6**: p. vi64-72.

49.	Schmoll, H.J., et al., *ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.* Ann Oncol, 2012. **23**(10): p. 2479-2516.

50.	Brenner, H., M. Kloor, and C.P. Pox, *Colorectal cancer.* Lancet, 2014. **383**(9927): p. 1490-1502.

51.	Lech, G., et al., *Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.* World J Gastroenterol, 2016. **22**(5): p. 1745-55.

52.	Berg, K.C.G., et al., *Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.* Mol Cancer, 2017. **16**(1): p. 116.

53.	Holst, S., et al., *N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression.* Mol Cell Proteomics, 2016. **15**(1): p. 124-40.

54.	Madunic, K., et al., *Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype.* Cell Mol Life Sci, 2020.

55.	van Gisbergen, K.P., et al., *Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin.* Cancer Res, 2005. **65**(13): p. 5935-44.

56.	Perdicchio, M., et al., *Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.* Proc Natl Acad Sci U S A, 2016. **113**(12): p. 3329-34.

57.	Cummings, R.D. and R.P. McEver, *C-Type Lectins*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 435-452.

58.	Geijtenbeek, T.B. and S.I. Gringhuis, *Signalling through C-type lectin receptors: shaping immune responses.* Nat Rev Immunol, 2009. **9**(7): p. 465-79.

59.	Reis, C.A., et al., *Alterations in glycosylation as biomarkers for cancer detection.* J Clin Pathol, 2010. **63**(4): p. 322-9.

60.	Ju, T., et al., *Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc.* Cancer Res, 2008. **68**(6): p. 1636-46.

61.	Ju, T., V.I. Otto, and R.D. Cummings, *The Tn antigen-structural simplicity and biological complexity.* Angew Chem Int Ed Engl, 2011. **50**(8): p. 1770-91.

62.	Fu, C., et al., *Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen.* HLA, 2016. **88**(6): p. 275-286.

63.	Rabinovich, G.A. and D.O. Croci, *Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer.* Immunity, 2012. **36**(3): p. 322-35.

64.	Vizcaino, J.A., et al., *2016 update of the PRIDE database and its related tools.* Nucleic Acids Res, 2016. **44**(22): p. 11033.

65.	Hinneburg, H., et al., *The Art of Destruction: Optimizing Collision Energies in Quadrupole-Time of Flight (Q-TOF) Instruments for Glycopeptide-Based Glycoproteomics.* J Am Soc Mass Spectrom, 2016. **27**(3): p. 507-19.

66.	Stavenhagen, K., et al., *Site-Specific N- and O-Glycopeptide Analysis Using an Integrated C18-PGC-LC-ESI-QTOF-MS/MS Approach.* Methods Mol Biol, 2017. **1503**: p. 109-119.

67.	Stavenhagen, K., et al., *N- and O-glycosylation Analysis of Human C1-inhibitor Reveals Extensive Mucin-type O-Glycosylation.* Mol Cell Proteomics, 2018. **17**(6): p. 1225-1238.

A

68. Liu, G., et al., *A Comprehensive, Open-source Platform for Mass Spectrometry-based Glycoproteomics Data Analysis.* Mol Cell Proteomics, 2017. **16**(11): p. 2032-2047.

69. Stadlmann, J., et al., *Comparative glycoproteomics of stem cells identifies new players in ricin toxicity.* Nature, 2017. **549**(7673): p. 538-542.

70. Joshi, H.J., et al., *GlycoDomainViewer: a bioinformatics tool for contextual exploration of glycoproteomes.* Glycobiology, 2018. **28**(3): p. 131-136.

71. Leitenberg, D., et al., *CD45-associated protein promotes the response of primary CD4 T cells to low-potency T-cell receptor (TCR) stimulation and facilitates CD45 association with CD3/TCR and lck.* Immunology, 2007. **121**(4): p. 545-54.

72. Gradogna, A., et al., *Subunit-dependent oxidative stress sensitivity of LRRC8 volume-regulated anion channels.* J Physiol, 2017. **595**(21): p. 6719-6733.

73. Voss, F.K., et al., *Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC.* Science, 2014. **344**(6184): p. 634-8.

74. Zheng, J., H. Xiao, and R. Wu, *Specific Identification of Glycoproteins Bearing the Tn Antigen in Human Cells.* Angew Chem Int Ed Engl, 2017. **56**(25): p. 7107-7111.

75. Marcelo, F., et al., *Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin.* Chemistry, 2014. **20**(49): p. 16147-55.

76. Duran-Struuck, R., et al., *A novel role for the semaphorin Sema4D in the induction of allo-responses.* Biol Blood Marrow Transplant, 2007. **13**(11): p. 1294-1303.

77. Kumanogoh, A. and H. Kikutani, *The CD100-CD72 interaction: a novel mechanism of immune regulation.* Trends Immunol, 2001. **22**(12): p. 670-6.

78. Velayos-Baeza, A., et al., *The dyslexia-associated gene KIAA0319 encodes highly N- and O-glycosylated plasma membrane and secreted isoforms.* Hum Mol Genet, 2008. **17**(6): p. 859-71.

79. Zjablovskaja, P., et al., *EVI2B is a C/EBPalpha target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.* Cell Death Differ, 2017. **24**(4): p. 705-716.

80. Hashiguchi, M., et al., *Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.* Proc Natl Acad Sci U S A, 2008. **105**(30): p. 10495-500.

81. Napoletano, C., et al., *Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation.* Eur J Immunol, 2012. **42**(4): p. 936-45.

82. van Vliet, S.J., et al., *MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-alpha secretion.* J Leukoc Biol, 2013. **94**(2): p. 315-23.

83. Sahasrabudhe, N.M., et al., *Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3.* Biol Chem, 2018. **399**(7): p. 649-659.

84. Soga, K., et al., *Terminal N-acetylgalactosamine-specific leguminous lectin from Wisteria japonica as a probe for human lung squamous cell carcinoma.* PLoS One, 2013. **8**(12): p. e83886.

85. Machado, E., et al., *N-Glycosylation of total cellular glycoproteins from the human ovarian carcinoma SKOV3 cell line and of recombinantly expressed human erythropoietin.* Glycobiology, 2011. **21**(3): p. 376-86.

86. Che, M.I., et al., *beta1, 4-N-acetylgalactosaminyltransferase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells.* Oncotarget, 2014. **5**(11): p. 3673-84.

87. Huang, J., et al., *Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells.* Mol Cancer Res, 2007. **5**(6): p. 543-52.

88. Haji-Ghassemi, O., et al., *Molecular Basis for Recognition of the Cancer Glycobiomarker, LacdiNAc (GalNAc[beta1-->4]GlcNAc), by Wisteria floribunda Agglutinin.* J Biol Chem, 2016. **291**(46): p. 24085-24095.

89.   Mortezai, N., et al., *Tumor-associated Neu5Ac-Tn and Neu5Gc-Tn antigens bind to C-type lectin CLEC10A (CD301, MGL).* Glycobiology, 2013. **23**(7): p. 844-52.

90.   Westen, A.A., et al., *Comparing six commercial autosomal STR kits in a large Dutch population sample.* Forensic Sci Int Genet, 2014. **10**: p. 55-63.

91.   Pirro, M., et al., *Glycoproteomic Analysis of MGL-Binding Proteins on Acute T-Cell Leukemia Cells.* J Proteome Res, 2019. **18**(3): p. 1125-1132.

92.   Sato, T., et al., *Molecular cloning and characterization of a novel human beta 1,4-N-acetylgalactosaminyltransferase, beta 4GalNAc-T3, responsible for the synthesis of N,N'-diacetyllactosediamine, galNAc beta 1-4GlcNAc.* J Biol Chem, 2003. **278**(48): p. 47534-44.

93.   Sun, X., T. Ju, and R.D. Cummings, *Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers.* BMC Cancer, 2018. **18**(1): p. 827.

94.   Yoo, N.J., M.S. Kim, and S.H. Lee, *Absence of COSMC gene mutations in breast and colorectal carcinomas.* APMIS, 2008. **116**(2): p. 154-5.

95.   Bard, F. and J. Chia, *Cracking the Glycome Encoder: Signaling, Trafficking, and Glycosylation.* Trends Cell Biol, 2016. **26**(5): p. 379-388.

96.   Gill, D.J., et al., *Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness.* Proc Natl Acad Sci U S A, 2013. **110**(34): p. E3152-61.

97.   Nguyen, A.T., et al., *Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.* Cancer Cell, 2017. **32**(5): p. 639-653 e6.

98.   Egea, G., et al., *cis-Golgi resident proteins and O-glycans are abnormally compartmentalized in the RER of colon cancer cells.* J Cell Sci, 1993. **105 (Pt 3)**: p. 819-30.

99.   Gibadullin, R., et al., *GalNAc-Tyrosine Is a Ligand of Plant Lectins, Antibodies, and Human and Murine Macrophage Galactose-Type Lectins.* ACS Chem Biol, 2017. **12**(8): p. 2172-2182.

100.   Chik, J.H., et al., *Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies.* J Proteomics, 2014. **108**: p. 146-62.

101.   Devine, P.L., et al., *Expression of MUC1 and MUC2 mucins by human tumor cell lines.* Tumour Biol, 1992. **13**(5-6): p. 268-77.

102.   Samame Perez-Vargas, J.C., et al., *Role of cMET in the development and progression of colorectal cancer.* Int J Mol Sci, 2013. **14**(9): p. 18056-77.

103.   Gout, S., et al., *Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation.* Cancer Res, 2006. **66**(18): p. 9117-24.

104.   Aychek, T., et al., *E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release.* Int J Cancer, 2008. **123**(8): p. 1741-50.

105.   Carrascal, M.A., et al., *A functional glycoproteomics approach identifies CD13 as a novel E-selectin ligand in breast cancer.* Biochim Biophys Acta Gen Subj, 2018. **1862**(9): p. 2069-2080.

106.   Carrascal, M.A., et al., *Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue.* BMC Cancer, 2018. **18**(1): p. 495.

107.   Tomlinson, J., et al., *Human colon cancer cells express multiple glycoprotein ligands for E-selectin.* Int J Oncol, 2000. **16**(2): p. 347-53.

108.   Cervoni, G.E., et al., *O-glycan recognition and function in mice and human cancers.* Biochem J, 2020. **477**(8): p. 1541-1564.

109.   Silva, M.L.S., *Lectin biosensors in cancer glycan biomarker detection.* Adv Clin Chem, 2019. **93**: p. 1-61.

110.   Pirro, M., et al., *Characterization of Macrophage Galactose-type Lectin (MGL) ligands in colorectal cancer cell lines.* Biochim Biophys Acta Gen Subj, 2020. **1864**(4): p. 129513.

111.   Paulo, J.A. and S.P. Gygi, *Nicotine-induced protein expression profiling reveals mutually altered proteins across four human cell lines.* Proteomics, 2017. **17**(1-2).

112.   Parizadeh, S.M., et al., *The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.* IUBMB Life, 2019. **71**(7): p. 802-811.

A

113.   Moriwaki, K., et al., *Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling.* Gastroenterology, 2009. **137**(1): p. 188-98, 198 e1-2.
114.   Saeland, E., et al., *Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients.* Int J Cancer, 2012. **131**(1): p. 117-28.
115.   Boyd, M., et al., *Genome-wide analysis of CDX2 binding in intestinal epithelial cells (Caco-2).* J Biol Chem, 2010. **285**(33): p. 25115-25.
116.   Lauc, G., et al., *Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation.* PLoS Genet, 2010. **6**(12): p. e1001256.
117.   Pinto, R., et al., *CDX2 homeoprotein is involved in the regulation of ST6GalNAc-I gene in intestinal metaplasia.* Lab Invest, 2015. **95**(7): p. 718-27.
118.   Holst, S., et al., *N-Glycomic and Transcriptomic Changes Associated with CDX1 mRNA Expression in Colorectal Cancer Cell Lines.* Cells, 2019. **8**(3).
119.   Conze, T., et al., *MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas.* Glycobiology, 2010. **20**(2): p. 199-206.
120.   Tjalsma, H., *Identification of biomarkers for colorectal cancer through proteomics-based approaches.* Expert Rev Proteomics, 2010. **7**(6): p. 879-95.
121.   de Wit, M., et al., *Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.* J Proteomics, 2014. **99**: p. 26-39.
122.   Makridakis, M. and A. Vlahou, *Secretome proteomics for discovery of cancer biomarkers.* J Proteomics, 2010. **73**(12): p. 2291-305.
123.   Karagiannis, G.S., M.P. Pavlou, and E.P. Diamandis, *Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology.* Mol Oncol, 2010. **4**(6): p. 496-510.
124.   Pirro, M., et al., *N-Glycoproteins Have a Major Role in MGL Binding to Colorectal Cancer Cell Lines: Associations with Overall Proteome Diversity.* Int J Mol Sci, 2020. **21**(15).
125.   Hou, S., et al., *Identification of the minimal N-glycosylation on integrin alpha5beta1 required for its inhibitory effect on EGFR signaling and cell proliferation.* Biochem Biophys Res Commun, 2020. **523**(1): p. 226-232.
126.   Xue, H., et al., *Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach.* J Proteome Res, 2010. **9**(1): p. 545-55.
127.   Celis, J.E., et al., *Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.* Mol Cell Proteomics, 2004. **3**(4): p. 327-44.
128.   Yu, C.J., et al., *Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology.* J Proteome Res, 2011. **10**(10): p. 4671-82.
129.   Gronborg, M., et al., *Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach.* Mol Cell Proteomics, 2006. **5**(1): p. 157-71.
130.   Napoletano, C., et al., *Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL).* Cancers (Basel), 2020. **12**(10).
131.   Brandi, J., et al., *Proteomic approaches to decipher cancer cell secretome.* Semin Cell Dev Biol, 2018. **78**: p. 93-101.
132.   Nickel, W. and C. Rabouille, *Mechanisms of regulated unconventional protein secretion.* Nat Rev Mol Cell Biol, 2009. **10**(2): p. 148-55.
133.   Akiyama, N., et al., *Enhancing activity of N-glycosylation for constitutive proteins secretions in non-polarized cells.* Biochem Biophys Res Commun, 2009. **381**(4): p. 612-8.
134.   Tuccillo, F.M., et al., *Aberrant glycosylation as biomarker for cancer: focus on CD43.* Biomed Res Int, 2014. **2014**: p. 742831.

135. Tamagnone, L. and G. Franzolin, *Targeting Semaphorin 4D in Cancer: A Look from Different Perspectives.* Cancer Res, 2019. **79**(20): p. 5146-5148.

136. Schlosser, A., et al., *Analysis of protein phosphorylation by a combination of elastase digestion and neutral loss tandem mass spectrometry.* Anal Chem, 2001. **73**(2): p. 170-6.

137. Trelle, M.B. and O.N. Jensen, *Utility of immonium ions for assignment of epsilon-N-acetyllysine-containing peptides by tandem mass spectrometry.* Anal Chem, 2008. **80**(9): p. 3422-30.

138. Caval, T., A.J.R. Heck, and K.R. Reiding, *Meta-heterogeneity: evaluating and describing the diversity in glycosylation between sites on the same glycoprotein.* Mol Cell Proteomics, 2020.

139. Reiding, K.R., et al., *The benefits of hybrid fragmentation methods for glycoproteomics.* Trac-Trends in Analytical Chemistry, 2018. **108**: p. 260-268.

140. Campbell, M.P., *A Review of Software Applications and Databases for the Interpretation of Glycopeptide Data.* Trends in Glycoscience and Glycotechnology, 2017. **29**(168): p. E51-E62.

141. Lee, L.Y., et al., *Toward Automated N-Glycopeptide Identification in Glycoproteomics.* J Proteome Res, 2016. **15**(10): p. 3904-3915.

142. Lu, L., et al., *O-Pair Search with MetaMorpheus for O-glycopeptide characterization.* Nat Methods, 2020. **17**(11): p. 1133-1138.

143. Steentoft, C., et al., *Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology.* EMBO J, 2013. **32**(10): p. 1478-88.

144. Ruhaak, L.R., et al., *Mass Spectrometry Approaches to Glycomic and Glycoproteomic Analyses.* Chem Rev, 2018. **118**(17): p. 7886-7930.

145. Shen, B., et al., *A novel strategy for global mapping of O-GlcNAc proteins and peptides using selective enzymatic deglycosylation, HILIC enrichment and mass spectrometry identification.* Talanta, 2017. **169**: p. 195-202.

146. Zachara, N., Y. Akimoto, and G.W. Hart, *The O-GlcNAc Modification*, in *Essentials of Glycobiology*, rd, et al., Editors. 2015: Cold Spring Harbor (NY). p. 239-251.

147. Halim, A., et al., *Assignment of saccharide identities through analysis of oxonium ion fragmentation profiles in LC-MS/MS of glycopeptides.* J Proteome Res, 2014. **13**(12): p. 6024-32.

148. Park, G.W., et al., *Classification of Mucin-Type O-Glycopeptides Using Higher-Energy Collisional Dissociation in Mass Spectrometry.* Anal Chem, 2020. **92**(14): p. 9772-9781.

149. Riley, N.M., et al., *Optimal Dissociation Methods Differ for N- and O-Glycopeptides.* J Proteome Res, 2020. **19**(8): p. 3286-3301.

150. Toghi Eshghi, S., et al., *Classification of Tandem Mass Spectra for Identification of N- and O-linked Glycopeptides.* Sci Rep, 2016. **6**: p. 37189.

151. Kall, L., et al., *Semi-supervised learning for peptide identification from shotgun proteomics datasets.* Nat Methods, 2007. **4**(11): p. 923-5.

152. Clarke, C., P. Rudland, and R. Barraclough, *The metastasis-inducing protein AGR2 is O-glycosylated upon secretion from mammary epithelial cells.* Mol Cell Biochem, 2015. **408**(1-2): p. 245-52.

153. Fessart, D., et al., *Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties.* Elife, 2016. **5**.

154. Ros, M., et al., *ER-resident oxidoreductases are glycosylated and trafficked to the cell surface to promote matrix degradation by tumour cells.* Nat Cell Biol, 2020. **22**(11): p. 1371-1381.

155. van Klinken, B.J., et al., *The human intestinal cell lines Caco-2 and LS174T as models to study cell-type specific mucin expression.* Glycoconj J, 1996. **13**(5): p. 757-68.

156. Schroeder, B.W., et al., *AGR2 is induced in asthma and promotes allergen-induced mucin overproduction.* Am J Respir Cell Mol Biol, 2012. **47**(2): p. 178-85.

157. Macher, B.A. and T.Y. Yen, *Proteins at membrane surfaces-a review of approaches.* Mol Biosyst, 2007. **3**(10): p. 705-13.

A

158.   Vit, O. and J. Petrak, *Integral membrane proteins in proteomics. How to break open the black box?* J Proteomics, 2017. **153**: p. 8-20.

159.   Laughlin, S.T., et al., *Metabolic labeling of glycans with azido sugars for visualization and glycoproteomics.* Methods Enzymol, 2006. **415**: p. 230-50.

160.   Torres-Gutierrez, E., et al., *Identification of O-Glcnacylated Proteins in Trypanosoma cruzi.* Front Endocrinol (Lausanne), 2019. **10**: p. 199.

161.   Ashkani, J. and K.J. Naidoo, *Glycosyltransferase Gene Expression Profiles Classify Cancer Types and Propose Prognostic Subtypes.* Sci Rep, 2016. **6**: p. 26451.

162.   Duarte, H.O., et al., *Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor.* Int J Mol Sci, 2017. **18**(11).

163.   Dall'Olio, F., et al., *Mechanisms of cancer-associated glycosylation changes.* Front Biosci (Landmark Ed), 2012. **17**: p. 670-99.

164.   Ferreira, I.G., et al., *Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling.* Int J Mol Sci, 2018. **19**(2).

165.   Chen, R., et al., *c-Met function requires N-linked glycosylation modification of pro-Met.* J Cell Biochem, 2013. **114**(4): p. 816-22.

166.   Qian, J., et al., *alpha2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells.* Acta Pharmacol Sin, 2009. **30**(7): p. 1039-45.

167.   Wu, Y.M., et al., *C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.* Cancer Res, 2013. **73**(17): p. 5580-90.

168.   Mereiter, S., et al., *Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer.* Front Oncol, 2016. **6**: p. 55.

169.   Zaal, A., et al., *Activation of the C-Type Lectin MGL by Terminal GalNAc Ligands Reduces the Glycolytic Activity of Human Dendritic Cells.* Front Immunol, 2020. **11**: p. 305.

170.   Gabba, A., et al., *Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to GalNAc and the Tumor-Associated Tn Antigen.* Biochemistry, 2021.

171.   Yin, S., et al., *Functional genomics analysis of human colon organoids identifies key transcription factors.* Physiol Genomics, 2020. **52**(6): p. 234-244.

Abbreviations

AGC	Automatic gain control
AGR2	Anterior gradient protein 2 homolog
Akt	Protein kinase B
APC	Adenomatous polyposis coli protein
APC	Antigen Presenting Cells
Arg	Arginine
BCA	Bicinchoninic acid
BRAF	Serine/threonine-protein kinase B-raf
CA	Carbohydrate antigen
CD3	T-cell surface glycoprotein CD3
CD43	Leukosialin
CD45	Receptor-type tyrosine-protein phosphatase C (PTPRC)
CDX	Caudal-related homeobox protein
CEA	Carcinoembryonic antigen
CID	collision-induced dissociation
CLR	C-type lectin receptor
CM	Conditioned medium
c-MET	Hepatocyte growth factor receptor
Cosmc	Core 1 beta-3-galactosyltransferase-specific molecular chaperone
CRC	Colorectal cancer
CRD	Carbohydrate recognition domain
Cys	Cysteine
DAG1	Dystroglycan
DC	Dendritic cell
DC-SIGN	Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin
DMEM	Dulbecco's Modified Eagle
DNA	Deoxyribonucleic acid
DTT	Ddithiothreitol
ECL	Enhanced chemiluminescence
ECM	Extracellular matrix
EDTA	Ethylenediaminetetraacetic acid
EGFR	Epithelial growth factor receptor
EGTA	Egtazic acid
ER	Endoplasmic reticulum
ETD	electron-transfer dissociation
EThcD	Electron-transfer/higher-energy collision dissociation
FA	Formic acid
FACS	Fluorescence-activated cell sorting
FBS	Foetal bovine serum
Fc	Fragment crystallizable
FDR	False discovery rate
FGF2	Fibroblast growth factor 2
FITC	Fluorescein isothiocyanate
FOBT	Fecal occult blood test
Fuc	Fucose
Gal	Galactose
GalNAc	N-Acetylgalactosamine
GALNT	N-Acetilgalactosaminyltransferase
GBPs	Glycan-binding proteins
GCNT	N-acetylglucosamine transferase
GDP	Guanosine diphosphate
Glc	Glucose
GlcA	Glucuronic acid
GlcNac	N-acetylglucosamine
GLG1	Golgi apparatus protein 1
GO	Gene Ontology
GOLMh	Golgi membrane protein 1
h	hour(s)
HCD	higher-energy collisional dissociation
HCF	Host cell factor
Hex	Hexose
HexNAc	N-acetylhexosamine
HGF	Hepatocyte growth factor
HILIC	Hydrophilic interaction liquid chromathography
His	Histidine
HLA	Human Leukocyte Antigen
HNF	Hepatocyte nuclear factor
HPLC	High-performance liquid chromatography
HRP	Horseradish peroxidase
IdoA	Iduronic acid
IFN	Interferon
IgG	Immunoglobulin G
IL	Interleukin
ITG	Integrin
JAK	Janus kinase
KIAA0319L	Dyslexia-associated protein KIAA0319-like protein
KRAS	GTPase KRas
LacdiNAc	N,N-diacetyllactosamine
LC	Liquid chromatography

A

Lck	Tyrosine-protein kinase Lck		RPMI	Roswell Park Memorial Institute
LeA	Lewis A		RT	Room temperature
LeB	Lewis B		SDS-PAGE	Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
Leu	Leucine		SELPLG	P-selectin glycoprotein ligand 1
LeX	Lewis X		SEMA	Semaphorin
LeY	Lewis Y		Ser	Serine
LLO	lipid linked oligosaccharide		Sia	Sialic Acid
LRCC	Leucine-rich repeat and coiled-coil domain-containing protein		SILAC	Stable Isotope Labeling by Amino acids in Cell culture
Lys	Lysine		sLeA	Sialyl Lewis A
M.W.	Molecular Weight		sLeX	Sialyl Lewis X
m/z	Mass-to-charge ratio		SORL1	Sortilin-related receptor
mAb	Monoclonal antibody		SPE	Solid-Phase Extraction
Man	Mannose		STAT	Signal transducer and activator of transcription
MAPK	Mitogen-activated protein kinase		sTn antigen	Sialyl Thomsen-nouvelle antigen
Met	Methionine			
MGAT5	Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase		STR	Short-tandem repeat
			T antigen	Thomsen-Friedenreich antigen
MGL/CLEC10/CD301	Macrophage galactose-type C-type lectin		T/Thr	Threonine
			TACA	Tumor-Associated Carbohydrate Antigens
MHC	major histocompatibility complex		TCEP	tris(2-carboxyethyl)phosphine
MS	Mass Spectrometry		TCL	Total cell lysate
MS/MS	tandem mass spectrometry		TCR	T-cell receptor
MSI	Microsatellite instability		TFA	Trifluoroacetic acid
MSS	Microsatellite stable		TFR1	Transferrin receptor protein 1
MUC	Mucin		TIMP1	Metalloproteinase inhibitor 1
N/Asn	Asparagine		TLR	Toll like receptor
NCE	Normalized collision energy		TMT	Tumor-Associated Carbohydrate Antigens Tandem Mass Tag
NeuAc	N-acetylneuraminic acid			
O/N	Over-night		Tn	Thomsen-nouvelle antigen
PBS	Phosphate Buffered Saline		TNF	Tumor necrosis factor
Phe	Phenilalanine		TP53	Cellular tumor antigen p53
PI3CA	PI3 kinase		TREML2	Trem-like transcript 2 protein
PI3K	Phosphatidylinositol 3-kinase		Trp	Thriptophan
PLA	Proximity ligation assay		Tyr	Tyrosine
PNGase F	Peptide N-Glycosidase F		UDP	Uridine diphosphate
			UPLC	Ultra Performance Liquid Chromatography
Pro	Proline			
PTK7	Inactive tyrosine-protein kinase 7		WB	Western Blot
PTPR	Receptor-type tyrosine-protein phosphatase		X	any amino acid
			Xyl	Xylose
PVDF	Polyvinylidene difluoride			
RNA	Ribonucleic acid			